About the Committee
BioNJ’s Public Policy Committee ensures that BioNJ has a position on relevant legislative and regulatory proposals and programs. The Committee is comprised of BioNJ Innovation Members who serve for a one-year term at the invitation of the Committee Chairman or Co-Chairmen and the President and CEO of BioNJ. The Committee meets on a quarterly or as-needed basis.
Ambaw Bellete, Photocure, Inc., Committee Chairman
James Sapirstein, R. Ph., MBA, ContraVir Pharmaceuticals, Inc.
George Coutros, Sanofi US
Sonia Delgado, PPAG
Robert Feeney, Ipsen
Debbie Hart, BioNJ
Paul G. Howes
Brian Kelly, Novo Nordisk
Wendy Lazarus, Pfizer
John Maki, Vicus Pharmaceuticals
Scott Megaffin, Churchill Pharmaceuticals
Daniel O’Connor, J.D.
Dmitri Siegel, Celgene Corporation
John Slotman, BioNJ